Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Apr 4;26(4):942-946.
doi: 10.1016/j.ymthe.2018.03.007. Epub 2018 Mar 21.

The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy

Richard G Vile  1
Affiliations
Comment

The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy

Richard G Vile. Mol Ther. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
NDV Oncolytic Viroimmunotherapy in a Virus-Naive Host
Figure 2
Figure 2
NDV Oncolytic Viroimmunotherapy Enhanced in a Virus Pre-immune Host
Figure 3
Figure 3
Local Intra-tumoral NDV Oncolytic Viroimmunotherapy in a Virus-Naive Host Is Effective against Distant Tumors
Figure 4
Figure 4
Local Intra-tumoral NDV Oncolytic Viroimmunotherapy in a Virus Immunized Host Is Enhanced against Distant Tumors
See this image and copyright information in PMC

Comment on

References

    1. Ricca J.M., Oseledchyk A., Walther T., Liu C., Mangarin L., Merghoub T., Wolchok J.D., Zamarin D. Pre-existing immnunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol. Ther. 2018;26:1008–1019. this issue. - PMC - PubMed
    1. Russell S.J. Replicating vectors for cancer therapy: a question of strategy. Semin. Cancer Biol. 1994;5:437–443. - PubMed
    1. Kirn D., Martuza R.L., Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 2001;7:781–787. - PubMed
    1. Cattaneo R., Miest T., Shashkova E.V., Barry M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 2008;6:529–540. - PMC - PubMed
    1. Zamarin D., Holmgaard R.B., Subudhi S.K., Park J.S., Mansour M., Palese P., Merghoub T., Wolchok J.D., Allison J.P. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 2014;6:226ra32. - PMC - PubMed

LinkOut - more resources